Shima Hadidchi MD Family Practice, we are committed to offering our patients the latest, evidence-based options for managing chronic conditions such as type 2 diabetes and obesity
A single accelerated dose does not exceed your prescribed amount and does not concentrate the drug to toxic levels in your bloodstream
It blocks the enzyme that makes pigment, shifts your skin toward producing less of the darker pigment type, and does this safely across all skin tones without the irritation risks that come with more aggressive depigmenting agents
Medications that were reliably available a year ago now occasionally sell out, especially at popular doses
Further research must be conducted on the additional potential benefits of DPP-4 inhibitors before the recommendation for DPP-4 inhibitors over SGLT2 inhibitors or GLP-1 agonists as a second-line agent for patients with type 2 diabetes can be strengthened
A new quintuple agonist tested in obese, insulin-resistant mice has shown superior efficacy in reducing body weight, improving glycemia, and enhancing lipid metabolism compared with GLP-1/GIP duals, pan-PPAR alone, or even combinations of the two